Literature DB >> 4137057

Measurement of circulating desialylated glycoproteins and correlation with hepatocellular damage.

J S Marshall, A M Green, J Pensky, S Williams, A Zinn, D M Carlson.   

Abstract

Addition of increasing amounts of (125)I-labeled desialylated thyroxine-binding globulin (DTBG) to hepatic cell membranes resulted in a progressive increase in binding. Saturability of membrane sites was indicated by a concentration beyond which further increases in [(125)I]DTBG resulted in no further binding. The binding curve for [(125)I]DTBG was similar to binding curves of desialylated orosomucoid, fetuin, and ceruloplasmin. An inhibition assay system using hepatic cell membranes showed that desialylated orosomucoid had a greater affinity for membrane binding sites than did DTBG but desialylated fetuin and ceruloplasmin bound less avidly than DTBG. Serum from normal persons and patients with a variety of illnesses was tested for its ability to inhibit [(125)I]DTBG binding. The inhibitory activity of 1 ml of normal serum was equivalent to that of 0.2-2 mug DTBG. Patients with Laënnec's cirrhosis, biliary cirrhosis, and hepatic metastases had greatly increased inhibitory activity in their serum. Patients with jaundice due to extrahepatic obstruction had inhibitory activity not significantly different from that found in normal serum. Column chromatography of normal serum on Sephadex G-200 resulted in inhibitory activity throughout the range of protein molecular weight. Desialylation of normal serum with neuraminidase enhanced the inhibitory activity but did not change the distribution of the activity. Gel chromatography of cirrhotic serum showed markedly increased inhibitory activity associated with the macroglobulins and the 4.5S peak and a new peak of inhibitory activity in the low molecular weight area was also seen. Inhibition of desialylated glycoprotein binding to liver cell membranes by serum from patients with hepatocellular disease raises the possibility that desialylated serum glycoproteins accumulate in the circulation and that patients with compromised hepatocellular function may no longer be able to clear them from the circulation. Alternatively, accumulation of desialylated glycoproteins in the circulation could result from defective protein synthesis by the diseased liver.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4137057      PMCID: PMC301588          DOI: 10.1172/JCI107792

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

1.  The structure of the glycopeptides of a human M-immunoglobulin.

Authors:  S Hickman; R Kornfeld; C K Osterland; S Kornfeld
Journal:  J Biol Chem       Date:  1972-04-10       Impact factor: 5.157

2.  Purification of neuraminidases from Vibrio Cholerae, Clostridium Perfringens and influenza virus by affinity chromatography.

Authors:  P Cuatrecasas; G Illiano
Journal:  Biochem Biophys Res Commun       Date:  1971-07-02       Impact factor: 3.575

3.  The structure of the glycopeptide of human gamma G myeloma proteins.

Authors:  R Kornfeld; J Keller; J Baenziger; S Kornfeld
Journal:  J Biol Chem       Date:  1971-05-25       Impact factor: 5.157

4.  Physical and chemical studies on ceruloplasmin. IX. The role of galactosyl residues in the clearance of ceruloplasmin from the circulation.

Authors:  C J Van Den Hamer; A G Morell; I H Scheinberg; J Hickman; G Ashwell
Journal:  J Biol Chem       Date:  1970-09-10       Impact factor: 5.157

5.  A modified method for the isolation of the plasma membrane from rat liver.

Authors:  T K Ray
Journal:  Biochim Biophys Acta       Date:  1970-01-06

6.  The binding of desialylated glycoproteins by plasma membranes of rat liver. Development of a quantitative inhibition assay.

Authors:  L Van Lenten; G Ashwell
Journal:  J Biol Chem       Date:  1972-07-25       Impact factor: 5.157

7.  Quantitative immunoelectrophoresis of serum proteins in cryptogenic cirrhosis, alcoholic cirrhosis and active chronic hepatitis.

Authors:  I M Murray-Lyon; H G Clarke; K McPherson; R Williams
Journal:  Clin Chim Acta       Date:  1972-06       Impact factor: 3.786

8.  The role of sialic acid in determining the survival of glycoproteins in the circulation.

Authors:  A G Morell; G Gregoriadis; I H Scheinberg; J Hickman; G Ashwell
Journal:  J Biol Chem       Date:  1971-03-10       Impact factor: 5.157

9.  Studies on thyroxine-binding globulin (TBG). II. Separation from human serum by affinity chromatography.

Authors:  J Pensky; J S Marshall
Journal:  Arch Biochem Biophys       Date:  1969-12       Impact factor: 4.013

10.  Radioimmunoassay of human thyroxine-binding globulin (TBG).

Authors:  R P Levy; J S Marshall; N L Velayo
Journal:  J Clin Endocrinol Metab       Date:  1971-03       Impact factor: 5.958

View more
  33 in total

1.  Serum glycoproteins in the liver diseases. I. Studies on sialic acid-free glycoproteins-improved competitive binding assay of desialylated glycoprotein by rat liver plasma membrane.

Authors:  T Arima; Y Motoyama; K Nagata; T Kondo
Journal:  Gastroenterol Jpn       Date:  1976

2.  Fused 99m-Tc-GSA SPECT/CT imaging for the preoperative evaluation of postoperative liver function: can the liver uptake index predict postoperative hepatic functional reserve?

Authors:  Morikatsu Yoshida; Shinya Shiraishi; Fumi Sakaguchi; Daisuke Utsunomiya; Kuniyuki Tashiro; Seiji Tomiguchi; Hirohisa Okabe; Toru Beppu; Hideo Baba; Yasuyuki Yamashita
Journal:  Jpn J Radiol       Date:  2012-04       Impact factor: 2.374

3.  Cancer-associated isoenzyme of serum galactosyltransferase.

Authors:  M M Weiser; D K Podolsky; K J Iselbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

4.  A hepatic receptor of avian origin capable of binding specifically modified glycoproteins.

Authors:  J Lunney; G Ashwell
Journal:  Proc Natl Acad Sci U S A       Date:  1976-02       Impact factor: 11.205

5.  Serum glycoproteins in the liver diseases. IV. Alpha-1 acid glycoprotein level in liver cirrhosis.

Authors:  T Arima; Y Motoyama; T Yamamoto; K Nagata; T Kondo
Journal:  Gastroenterol Jpn       Date:  1977

6.  Dysfibrinogenemia associated with liver disease.

Authors:  J E Palascak; J Martinez
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

7.  Serum glycoproteins in the liver diseases. III. Desialylated glycoproteins in the acute hepatitis.

Authors:  T Arima; Y Motoyama; T Yamamoto; K Nagata; T Kondo
Journal:  Gastroenterol Jpn       Date:  1977

8.  Serum glycoproteins in the liver diseases. V. Desialylated glycoproteins in chronic hepatitis.

Authors:  T Arima; Y Motoyama; T Yamamoto; K Nagata; T Kondo; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1978

9.  Serum glycoproteins in the liver diseases. VI. The presence of desialylated glycoprotein binding activity in particulate fraction of human liver homogenate.

Authors:  T Arima; T Kondo; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1978

10.  Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease.

Authors:  J Martinez; J E Palascak; D Kwasniak
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.